Kyverna Initiates Rolling BLA Submission for miv-cel in Stiff Person Syndrome, Reports Strong Q1 Results
KYTX has more than doubled off its 52-week low of $2.06.
Summary
Kyverna Therapeutics initiated its rolling BLA submission for miv-cel in Stiff Person Syndrome, a major regulatory milestone, alongside reporting strong Q1 financials and a cash runway into 2028.
Key Events · Product Development and Regulatory · KYTX
-
BLA Submission Initiated for miv-cel in SPS
Kyverna began a rolling Biologics License Application (BLA) submission to the FDA for miv-cel in Stiff Person Syndrome (SPS), with FDA alignment on using a single-arm Phase 2 trial (KYSA-8) for support. The company expects to complete the submission in Q4 2026 and is seeking priority review under RMAT designation.
-
Strong Q1 Financial Results
The company reported a net loss of $39.7 million for Q1 2026, an improvement from $44.6 million in Q1 2025. Cash, cash equivalents, and marketable securities stood at $236.4 million as of March 31, 2026, providing a cash runway into 2028.
-
Positive Clinical Data Updates
Enrollment is advancing in the Phase 3 trial for generalized myasthenia gravis (gMG), supported by durable one-year efficacy data from the Phase 2 portion. Positive follow-up data for miv-cel in Progressive Multiple Sclerosis (PMS) were also presented.
-
Commercial Readiness
Kyverna appointed Nadia Dac as Chief Commercial Officer and is advancing launch-readiness activities for miv-cel in SPS, with current manufacturing capacity expected to support commercial launch.
Analysis · KYTX · Life Sciences
Kyverna Therapeutics has initiated a rolling Biologics License Application (BLA) submission to the FDA for its lead CAR T-cell therapy, miv-cel, in Stiff Person Syndrome (SPS). This follows positive alignment with the FDA on using a single-arm Phase 2 trial (KYSA-8) to support the BLA, and the company is seeking priority review under its Regenerative Medicine Advanced Therapy (RMAT) designation. This marks a critical de-risking step towards commercialization for a first-in-class autoimmune CAR T therapy. The company also reported a reduced net loss and a strong cash position of $236.4 million, extending its cash runway into 2028, providing ample resources for continued development and launch preparations.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KYTX was trading at $10.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $619.2M. The 52-week trading range was $2.06 to $13.67. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.